MYL’s Symfi Lo is a 3-DAA FDC positioned as replacement for GILD’a Atripla; it contains the constituents in Atripla except that Lamivudine has been substituted for Emtriva (which is still on-patent in the US).
MYL’s Cimduo is a 2-DAA FDC positioned as a replacement for GILD’s Truvada, where (as above) Lamivudine has been substituted for Emtriva.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.